Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to a delivery mechanism having one or more balloons or other expandable devices which are expandable responsive to a condition in the small intestine or other GI lumen to advance the preparation out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Described herein are oral delivery systems for use in delivering live mammalian cells to the intestinal tract of an individual.

The present invention relates to stable oral composition comprising linaclotide or its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates, process of preparation thereof and methods of using the same.

Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Methods of manufacture of nut flours and/or formulations, ultra-low fat nut flours and uses for nut flour formulations. In some embodiments, methods of manufacturing ultra-low fat tree nut or peanut flour formulations for oral administration in immunotherapy of subjects affected by allergies.

Capsule devices, such as devices suitable for swallowing into a lumen of a body lumen, are generally provided. In some embodiments, the capsule device (100) comprises a tissue interfacing component (130) disposed relative to a capsule housing (110,120). The capsule device (100) may comprise a plurality of elongated spike members (182, 130) advanceable relative to the capsule housing (110,120) from a non-advanced first state to an advanced second state, wherein free ends of the elongated spike members (182, 130) engages tissue of a lumen wall of the body lumen. In some embodiments, the capsule device (100) comprises an actuator (155) coupled to the plurality of elongate spike members (182) and an energy source (140) coupled to the actuator (155) for moving the plurality of elongated spike members (182, 130) to the advanced second state. At least one of the plurality of spike members (182, 130) is configured as a deflectable spike member (182) that is deflected laterally as the deflectable spike member is advanced toward the second state so that the plurality of spike members (182, 130) act by spreading or pinching engagement on tissue between the plurality of spike members, thereby anchoring the capsule device (100) relative to the lumen wall.

Described herein are implantable devices comprising cells engineered to express and secrete antigens of infectious agents. The devices are useful for inducing protective immune responses against infectious agents.

Solid pharmaceutical formulations including AZD4635 are described. The solid formulations can include a polymeric stabilizer (e.g., a polyvinylpyrollidone), an ionic surfactant (e.g., sodium docusate), and a non-ionic surfactant (e.g., a poloxamer).

A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

The present invention belongs to the pharmaceutical field, and in particular, it relates to a pharmaceutical formulation of palbociclib and a preparation method thereof. The pharmaceutical formulation comprises palbociclib, an acidic auxiliary material, and optionally a hydrophilic high-molecular material, which has better solubility and in vitro dissolution property as compared with the conventional formulation and can be used for enhancing in vivo absorption and bioavailability of palbociclib.